|
Arshine Group Co.,Ltd.
|
Brimonidine L-tartrate is a pharmaceutical compound used primarily in ophthalmic solutions to treat conditions like glaucoma and ocular hypertension. It falls under the category of alpha-adrenergic agonists and works by decreasing the fluid production in the eye, thereby reducing intraocular pressure.
A typical product description for Brimonidine L-tartrate powder might include:
- Chemical Name: Brimonidine L-tartrate
- Chemical Formula: C11H10BrN5.C4H6O6
- Appearance: White to off-white crystalline powder
- Solubility: Soluble in water and sparingly soluble in alcohol.
- Pharmacological Action: Acts as an alpha-adrenergic agonist, selectively binding to alpha receptors in the eye, thereby reducing intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
- Medical Uses: Formulated into ophthalmic solutions for the treatment of glaucoma and ocular hypertension.
- Dosage Forms: Typically available in the form of eye drops or ophthalmic solutions.
- Dosage and Administration: The dosage and frequency of administration depend on the severity of the condition and the doctor's prescription. Usually, it's applied topically to the affected eye(s) as directed.
- Safety and Precautions: While generally safe, Brimonidine L-tartrate may cause side effects such as ocular irritation, dry mouth, fatigue, or changes in blood pressure. It should be used cautiously, especially in patients with cardiovascular diseases or depression.
- Storage: It should be stored in a dry place at room temperature, away from light and moisture.
As with any medication, it's crucial to use Brimonidine L-tartrate as prescribed by a healthcare professional to avoid potential adverse effects and to maximize its therapeutic benefits for the specific eye condition being treated.
|
Product Name
|
Brimonidine Tartrate
|
|
CAS No.
|
70359-46-5
|
|
Production Date
|
Mar.09,2022
|
Report Date
|
Mar.14,2022
|
|
Batch No
|
IFP07-220301
|
Retest Date
|
Mar.08,2024
|
|
Quantity
|
10.3Kg
|
Packing
|
1kg/Alu
minium
bag
|
|
ITEMS
|
SPECIFICATION
|
RESULTS
|
|
Appearance
|
White or slightly yellowish or slightly brownish powder
|
Conforms
|
|
Identification
|
A:Specific optical rotation
B:Infrared absorption spectrophotometry
|
Conforms
Conforms
|
|
Solubility
|
Soluble in water,practically insoluble in anhydrous ethanol and in toluene
|
Conforms
|
|
Loss on Drying
|
≤0.50%
|
0.25%
|
|
Heavy Metals
|
≤20ppm
|
Conforms
|
|
Sulfated Ash
|
≤0.20%
|
0.09%
|
|
Specific Optical Rotation
|
+9.0° - +10.5°
|
+9.8°
|
|
Residual Solvents
|
Bromobenzene≤290ppm
Acetone≤3000ppm
|
Conforms
Conforms
|
|
Related Substances
|
Specified impurities:
N-(imidazolidin2ylidene)quinoxalin-6-amine≤0.1% 5-bromoquinoxalin-6-amine≤0.1%
Quinoxalin-6-amine≤0.1%
1-(5-bromoquinoxalin-6-yl)thiourea≤0.1%
2-(5-bromoquinoxalin6yl)guanidine≤0.1%
5-bromo-N-(1H-imidazol-2-yl)Quinoxalin-6-amine≤0.1% -(2-aminoethyl)-3-(5-bromoquinoxalin-6-yl)urea≤0.19 Unspecified impurities≤0.1%
Total≤0.2%
|
Conforms
Conforms
Conforms
Conforms
Conforms
Conforms
Conforms
Conforms
0.14%
|
|
Assay(On Dried
Basis)
|
99.0%-101.0%
|
100.1%
|
|
Packaging and Storage
|
Preserve in tight containers,protected from light
|
|
Conclusion
|
The product complies with BP2015 Standard
|
|
Send Inquiry
|
Pharma Sources Insight January 2025
